6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 17 May,2004 By /s/Ronald Lea Erratt Company Secretary

ASX MEDIA RELEASE
17 MAY 2004

THE UNIVERSITY OF SYDNEY HONORS MARSHALL EDWARDS, INC. CHAIRMAN.

Novogen Limited's subsidiary, Marshall Edwards, Inc.,
(LSE AIM: MSH and Nasdaq: MSHL) has just made the following
announcement to the London Stock Exchange's Alternative
Investment Market regarding Novogen Limited Director, Graham Kelly.

WASHINGTON, DC, 17 May, 2004 Marshall Edwards, Inc.,
(NASDAQ: MSHL). The Chairman of Marshall Edwards, Inc.,
Graham Kelly BSc(Vet), BVSc, PhD, has been appointed an
Adjunct Professor of The University of Sydney.

The University of Sydney is the oldest and one of the
most prestigious tertiary institutions in Australia,
and over the past 150 years has built an international
reputation. It is Australia's leading research
intensive university.

Professor Kelly has been honored for his continuing
contribution to research by his alma mater, the Faculty
of Veterinary Science.

Marshall Edwards, Inc., is engaged in clinical trials
of the anti-cancer drug phenoxodiol, and has the
license to develop and commercialize phenoxodiol
and certain other anti-cancer compounds from
Novogen Limited. Professor Kelly founded
Novogen Limited (Nasdaq: NVGN; ASX : NRT) which
first listed in 1994.

Much of the early research work underpinning the Group's
intellectual property was undertaken by Professor Kelly,
who worked in the Department of Experimental Surgery,
in the Faculty of Medicine, at the University of Sydney,
during the 1970s and 1980s.

President and CEO of Marshall Edwards, Inc.,
Christopher Naughton, said the Company was delighted
that the research contributions made by Professor Kelly
have been acknowledged, encouraged and supported by
this appointment.

"Professor Kelly's appointment also strengthens the
ongoing scientific research and commercial
collaboration that both Novogen and Marshall
Edwards have fostered with the University of Sydney
over recent years," Mr. Naughton said.

Marshall Edwards Inc is 87% owned by Novogen Limited.

More information on phenoxodiol and on the Novogen
group of companies can be found at
www.marshalledwardsinc.com and www.novogen.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088